Dako Enters into an Additional Collaboration with Amgen
News Feb 28, 2012
Dako has announced that it has entered into a new collaboration agreement with Amgen Inc. on the development of a diagnostic test for an Amgen cancer drug candidate in clinical development.
“It is Dako’s mission to fight cancer. Hence, we are pleased to be chosen as Amgen’s partner once again for the development of companion diagnostics linked to Amgen’s investigational targeted therapies,” says Lars Holmkvist, Dako’s chief executive officer.
In January 2012, Dako announced a collaboration agreement with Amgen Inc. introducing a new business model which supports the concurrent development of drug and diagnostics for a rare but deadly cancer - something that up to this point has been difficult to achieve in the industry.
“This new collaboration with Amgen underlines Dako’s commitment to advance personalized medicine in cancer treatment as the selection of patients most likely to benefit from a specific treatment will increase the probability of therapeutic success for cancer patients suffering," Lars Holmkvist adds.
Today’s news comes on the heels of several pharmDx™ collaborative agreements recently announced by Dako.
The demand for personalized medicine is increasing with the recognition that it may provide a way to improve patient care and manage healthcare costs by targeting treatments to individuals more likely to benefit from specific therapies.
New Cell-weighing Technique Helps Predict How Drugs Affect Cancer CellsNews
Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple-myeloma patients.READ MORE
Computer Program Helps Find Ways to Repurpose Existing DrugsNews
Researchers have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, matches existing data about FDA-approved drugs to diseases, and predicts potential drug efficacy.READ MORE